---
title: "Tolazoline - Cerebrovascular Disease"
sidebar: mydoc_sidebar
permalink: db00797-mesh-d002561-1.html
toc: false 
---


Path ID: `DB00797_MESH_D002561_1`
{% include image.html url="images/db00797-mesh-d002561-1.png" file="db00797-mesh-d002561-1.png" alt="db00797-mesh-d002561-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| <a href="https://identifiers.org/MESH:D014043">MESH:D014043 </a> | tolazoline | Drug |
| <a href="https://identifiers.org/UniProt:P35367">UniProt:P35367 </a> | Histamine H1 receptor | Protein |
| <a href="https://identifiers.org/UniProt:P25021">UniProt:P25021 </a> | Histamine H2 receptor | Protein |
| <a href="https://identifiers.org/UniProt:P35348">UniProt:P35348 </a> | Alpha-1A adrenergic receptor | Protein |
| <a href="https://identifiers.org/UniProt:P08913">UniProt:P08913 </a> | Alpha-2A adrenergic receptor | Protein |
| <a href="https://identifiers.org/UniProt:P18089">UniProt:P18089 </a> | Alpha-2B adrenergic receptor | Protein |
| <a href="https://identifiers.org/UniProt:P18825">UniProt:P18825 </a> | Alpha-2C adrenergic receptor | Protein |
| <a href="https://identifiers.org/reactome:R-HSA-416476">reactome:R-HSA-416476 </a> | G alpha (q) signalling events | Pathway |
| <a href="https://identifiers.org/reactome:R-HSA-416482">reactome:R-HSA-416482 </a> | G alpha (12/13) signalling events | Pathway |
| <a href="https://identifiers.org/reactome:R-HSA-418594">reactome:R-HSA-418594 </a> | G alpha (i) signalling events | Pathway |
| <a href="https://identifiers.org/reactome:R-HSA-418597">reactome:R-HSA-418597 </a> | G alpha (z) signalling events | Pathway |
| <a href="https://identifiers.org/GO:0042310">GO:0042310 </a> | vasoconstriction | BiologicalProcess |
| <a href="https://identifiers.org/GO:0042311">GO:0042311 </a> | vasodilation | BiologicalProcess |
| <a href="https://identifiers.org/MESH:D002561">MESH:D002561 </a> | Cerebrovascular disease | Disease |
|------------|------|---------|

## Relationships


NOTE: predicates are annotated in <a href="https://github.com/biolink/biolink-model/releases/tag/v1.3.0">Biolink Model (v1.3.0)</a>

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Tolazoline | POSITIVELY REGULATES | Histamine H1 Receptor |
| Tolazoline | POSITIVELY REGULATES | Histamine H2 Receptor |
| Histamine H1 Receptor | POSITIVELY REGULATES | Vasodilation |
| Histamine H2 Receptor | POSITIVELY REGULATES | Vasodilation |
| Vasodilation | NEGATIVELY CORRELATED WITH | Cerebrovascular Disease |
| Tolazoline | NEGATIVELY REGULATES | Alpha-1A Adrenergic Receptor |
| Tolazoline | NEGATIVELY REGULATES | Alpha-2A Adrenergic Receptor |
| Tolazoline | NEGATIVELY REGULATES | Alpha-2B Adrenergic Receptor |
| Tolazoline | NEGATIVELY REGULATES | Alpha-2C Adrenergic Receptor |
| Alpha-1A Adrenergic Receptor | PARTICIPATES IN | G Alpha (Q) Signalling Events |
| Alpha-1A Adrenergic Receptor | PARTICIPATES IN | G Alpha (12/13) Signalling Events |
| Alpha-2A Adrenergic Receptor | PARTICIPATES IN | G Alpha (I) Signalling Events |
| Alpha-2A Adrenergic Receptor | PARTICIPATES IN | G Alpha (Z) Signalling Events |
| Alpha-2B Adrenergic Receptor | PARTICIPATES IN | G Alpha (I) Signalling Events |
| Alpha-2B Adrenergic Receptor | PARTICIPATES IN | G Alpha (Z) Signalling Events |
| Alpha-2C Adrenergic Receptor | PARTICIPATES IN | G Alpha (I) Signalling Events |
| Alpha-2C Adrenergic Receptor | PARTICIPATES IN | G Alpha (Z) Signalling Events |
| G Alpha (Q) Signalling Events | POSITIVELY REGULATES | Vasoconstriction |
| G Alpha (12/13) Signalling Events | POSITIVELY REGULATES | Vasoconstriction |
| G Alpha (I) Signalling Events | POSITIVELY REGULATES | Vasoconstriction |
| G Alpha (Z) Signalling Events | POSITIVELY REGULATES | Vasoconstriction |
| Vasoconstriction | POSITIVELY CORRELATED WITH | Cerebrovascular Disease |
|---------|-----------|---------|

Reference: 
  - [https://go.drugbank.com/drugs/DB00797#mechanism-of-action](https://go.drugbank.com/drugs/DB00797#mechanism-of-action)
  - [https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL770/](https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL770/)
  - [https://en.wikipedia.org/wiki/Cerebrovascular_disease#Treatment](https://en.wikipedia.org/wiki/Cerebrovascular_disease#Treatment)
